Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest update is out from Monte Rosa Therapeutics ( (GLUE) ).
On December 16, 2025, Monte Rosa Therapeutics announced positive interim results from its Phase 1/2 clinical study of MRT-2359 combined with enzalutamide in heavily pretreated metastatic castration-resistant prostate cancer patients. The study showed a 100% PSA response rate in patients with androgen receptor mutations, and the combination treatment maintained a favorable safety profile. The company plans to initiate a Phase 2 study in 2026 to further assess MRT-2359’s efficacy, potentially expanding the study to include additional patient subsets.
The most recent analyst rating on (GLUE) stock is a Buy with a $22.00 price target. To see the full list of analyst forecasts on Monte Rosa Therapeutics stock, see the GLUE Stock Forecast page.
Spark’s Take on GLUE Stock
According to Spark, TipRanks’ AI Analyst, GLUE is a Neutral.
Monte Rosa Therapeutics exhibits strengths in clinical progress and a robust financial runway, counterbalanced by ongoing profitability issues and bearish technical indications. While clinical advancements and strategic partnerships offer growth potential, the negative P/E ratio and reliance on external funding present risks.
To see Spark’s full report on GLUE stock, click here.
More about Monte Rosa Therapeutics
Monte Rosa Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing novel molecular glue degrader (MGD)-based medicines. The company is involved in creating treatments for various conditions, including castration-resistant prostate cancer and inflammatory diseases.
Average Trading Volume: 1,045,134
Technical Sentiment Signal: Buy
Current Market Cap: $1.06B
See more insights into GLUE stock on TipRanks’ Stock Analysis page.